Clinical Trial Update: Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports tolerability and early efficacy data for the combination of tremelimumab with gefitinib in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: COMPLETED